Drug Profile
Oxymetazoline - 9 Meters Biopharma
Alternative Names: RDD 0315Latest Information Update: 09 Oct 2021
Price :
$50
*
At a glance
- Originator RDD Pharma
- Developer 9 Meters Biopharma
- Class Eye disorder therapies; Imidazoles; Small molecules
- Mechanism of Action Alpha adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Faecal incontinence
Most Recent Events
- 29 Sep 2021 Discontinued - Phase-I for Faecal Incontinence (In volunteers) in USA (Rectal) prior to September 2021 (9 Meters Biopharma pipeline, September 2021)
- 29 Sep 2021 Discontinued - Phase-II for Faecal Incontinence in Hungary (Rectal) prior to September 2021 (9 Meters Biopharma pipeline, September 2021)
- 28 Sep 2021 No recent reports of development identified for phase-I development in Faecal-Incontinence(In volunteers) in USA (Rectal, Gel)